Pancreatic cancer remains the most lethal form of cancer, with a 5-year survival rate of only 10%. Increasingly, Claudin 18.2 (CLDN18.2) has emerged as a promising therapeutic target, with several ongoing studies investigating its potential in pancreatic carcinoma. Building on this growing interest, our study aims to address critical gaps in the standardization and validation of CLDN18 immunohistochemistry (IHC) methodologies for pancreatic cancer.
